Taiwan
· Delayed Price · Currency is TWD Hantech Bio-Technology Statistics
Total Valuation
Hantech Bio-Technology has a market cap or net worth of TWD 2.64 billion. The enterprise value is 2.78 billion.
| Market Cap | 2.64B |
| Enterprise Value | 2.78B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | Jun 6, 2024 |
Share Statistics
Hantech Bio-Technology has 25.24 million shares outstanding.
| Shares Outstanding | 25.24M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 21.24M |
Valuation Ratios
The trailing PE ratio is 15.14.
| PE Ratio | 15.14 |
| Forward PE | n/a |
| PS Ratio | 3.40 |
| PB Ratio | 5.72 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.93, with an EV/FCF ratio of -21.76.
| EV / Earnings | 15.51 |
| EV / Sales | 3.58 |
| EV / EBITDA | 10.93 |
| EV / EBIT | 12.15 |
| EV / FCF | -21.76 |
Financial Position
The company has a current ratio of 1.56, with a Debt / Equity ratio of 0.63.
| Current Ratio | 1.56 |
| Quick Ratio | 1.14 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 1.16 |
| Debt / FCF | -2.31 |
| Interest Coverage | 49.25 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 5.10M |
| Profits Per Employee | 1.18M |
| Employee Count | 152 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.37% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +12.37% |
| 50-Day Moving Average | 148.51 |
| 200-Day Moving Average | 162.03 |
| Relative Strength Index (RSI) | 26.90 |
| Average Volume (20 Days) | 201,373 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hantech Bio-Technology had revenue of TWD 774.78 million and earned 178.96 million in profits. Earnings per share was 6.90.
| Revenue | 774.78M |
| Gross Profit | 336.38M |
| Operating Income | 228.57M |
| Pretax Income | 225.65M |
| Net Income | 178.96M |
| EBITDA | 247.45M |
| EBIT | 228.57M |
| Earnings Per Share (EPS) | 6.90 |
Balance Sheet
The company has 158.61 million in cash and 294.21 million in debt, giving a net cash position of -135.60 million or -5.37 per share.
| Cash & Cash Equivalents | 158.61M |
| Total Debt | 294.21M |
| Net Cash | -135.60M |
| Net Cash Per Share | -5.37 |
| Equity (Book Value) | 464.40M |
| Book Value Per Share | 18.27 |
| Working Capital | 140.80M |
Cash Flow
In the last 12 months, operating cash flow was 144.46 million and capital expenditures -272.07 million, giving a free cash flow of -127.61 million.
| Operating Cash Flow | 144.46M |
| Capital Expenditures | -272.07M |
| Free Cash Flow | -127.61M |
| FCF Per Share | -5.06 |
Margins
Gross margin is 43.42%, with operating and profit margins of 29.50% and 23.10%.
| Gross Margin | 43.42% |
| Operating Margin | 29.50% |
| Pretax Margin | 29.12% |
| Profit Margin | 23.10% |
| EBITDA Margin | 31.94% |
| EBIT Margin | 29.50% |
| FCF Margin | -16.47% |
Dividends & Yields
This stock pays an annual dividend of 0.77, which amounts to a dividend yield of 0.74%.
| Dividend Per Share | 0.77 |
| Dividend Yield | 0.74% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 9.41% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.74% |
| Earnings Yield | 6.61% |
| FCF Yield | -4.84% |
Stock Splits
The last stock split was on June 6, 2024. It was a forward split with a ratio of 1.3.
| Last Split Date | Jun 6, 2024 |
| Split Type | Forward |
| Split Ratio | 1.3 |
Scores
Hantech Bio-Technology has an Altman Z-Score of 5.21.
| Altman Z-Score | 5.21 |
| Piotroski F-Score | n/a |